LinkedIn
Specialty
Course Type
Search
Log In
Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In
Menu

Then, Now, and Tomorrow: Evolving the Management of Diabetic Retinopathy and the Role of the Optometrist – Tampa

By: David Eichenbaum, MD

Begin Course
In Person Credits: 2

Expiration Date: Saturday, February 29, 2020
Release Date: December 11, 2019

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss the increasing prevalence of diabetes and diabetic retinopathy.
  • Identify which patients need to be screened earlier based on their disease state.
  • Summarize how imaging devices may be able to provide earlier diagnosis of disease or disease progression.
  • Explain to patients the need for early and timely referral to retina specialists.
  • Understand the evolving treatment paradigm of diabetic eye disease.

Accreditation and Designation Statement

Evolve is an approved COPE Administrator

This course is COPE approved for 1.25 hours of CE Credit for Optometrists:

COPE Course ID: 65397-PS

COPE Activity ID: 118502 

 

Faculty and Disclosures

The following faculty/staff members have the following financial relationships with commercial interests:

David Eichenbaum, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech, Regeneron, Allergan, Clearside, Novartis, Alimera, Notal Vision, Allegro, EyePoint, Orbit Biomedical, Adverum, Kodiak; Speaker: Genentech, Allergan, Novartis, Notal Vision; Investigator: Genentech, Allergan, Clearside, Novartis, Alimera, Ophthotech, Opthea, Mylan, Chengdu, Kodiak; Equity/Stockholder: Clearside, US Retina, Hemera Biopharmaceuticals, Boston Image Reading Center.

Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education, Evolve and Susan Gallagher-Pecha, director of client services and project management, Evolve, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan.

 

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Regeneron Pharmaceuticals, Inc. or Carl Zeiss Meditec Inc.

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Pretest

  • 1 Not at all confident23 Neutral45 Very Confident
  • 1 Not at all confident23 Neutral45 Very Confident

Test

Instructions

Step 1 of 3

33%
  • AgreeNeutralDisagree
    • Discuss the increasing prevalence of diabetes and diabetic retinopathy
    • Identify which patients need to be screened earlier based on their disease state
    • Explain to patients the need for early referral to retina specialists
    • Summarize how diabetic eye disease may affect patients with visually significant cataract and initiate appropriate treatment for these patients.
    • Discuss how imaging devices may be able to provide earlier diagnosis of disease or disease progression.
Back